Stonepine Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Stonepine Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Sell	224,989 -110,320	-33%	-$453K	0.59%	39
2026 Q1	$1.38M	Sell	335,309 -258,264	-44%	-$967K	0.55%	29
2025 Q4	$2.37M	Sell	593,573 -462,765	-44%	-$1.68M	1.73%	19
2025 Q3	$3.61M	Buy	+1,056,338	New	+$2.72M	2.94%	10
2023 Q4	–	Sell	-175,790	Closed	-$5.75M	–	22
2023 Q3	$5.75M	Buy	175,790 +22,281	+15%	+$972K	1.91%	13
2023 Q2	$8.93M	Buy	+153,509	New	+$7.89M	3.22%	10

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stonepine Capital Management's XFOR Position: Q2 2026 in Review

Stonepine Capital Management reduced its X4 Pharmaceuticals (XFOR) stake by 33% in Q2 2026, selling an estimated $453K and leaving 224,989 shares worth $1.05M. The position accounts for 0.59% of the portfolio, ranked #39.

Stonepine Capital Management first reported a position in XFOR in Q2 2023 and has held it in 6 quarters since. The position peaked at $8.93M in Q2 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Stonepine Capital Management held 224,989 shares of X4 Pharmaceuticals worth $1.05M as of Q2 2026.
Stonepine Capital Management sold 110,320 X4 Pharmaceuticals shares in Q2 2026, an estimated $453K.
X4 Pharmaceuticals made up 0.59% of Stonepine Capital Management's portfolio in Q2 2026, its #39 holding.
Stonepine Capital Management first reported a position in X4 Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
Stonepine Capital Management's X4 Pharmaceuticals position peaked at $8.93M in Q2 2023.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.